Elsevier

The Lancet

Volume 373, Issue 9677, 23–29 May 2009, Pages 1765-1772
The Lancet

Articles
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

https://doi.org/10.1016/S0140-6736(09)60697-8Get rights and content

Summary

Background

Whether intensive control of glucose reduces macrovascular events and all-cause mortality in individuals with type 2 diabetes mellitus is unclear. We undertook a meta-analysis of randomised controlled trials to determine whether intensive treatment is beneficial.

Methods

We selected five prospective randomised controlled trials of 33 040 participants to assess the effect of an intensive glucose-lowering regimen on death and cardiovascular outcomes compared with a standard regimen. We gathered information about events of non-fatal myocardial infarction, coronary heart disease (fatal and non-fatal myocardial infarction), stroke, and all-cause mortality, and did a random-effects meta-analysis to obtain summary effect estimates for the clinical outcomes with use of odds ratios calculated from the raw data of every trial. Statistical heterogeneity across trials was assessed with the χ2 and I2 statistics.

Findings

The five trials provided information on 1497 events of non-fatal myocardial infarction, 2318 of coronary heart disease, 1127 of stroke, and 2892 of all-cause mortality during about 163 000 person-years of follow-up. The mean haemoglobin A1c concentration (HbA1c) was 0·9% lower for participants given intensive treatment than for those given standard treatment. Intensive glycaemic control resulted in a 17% reduction in events of non-fatal myocardial infarction (odds ratio 0·83, 95% CI 0·75–0·93), and a 15% reduction in events of coronary heart disease (0·85, 0·77–0·93). Intensive glycaemic control had no significant effect on events of stroke (0·93, 0·81–1·06) or all-cause mortality (1·02, 0·87–1·19).

Interpretation

Overall, intensive compared with standard glycaemic control significantly reduces coronary events without an increased risk of death. However, the optimum mechanism, speed, and extent of HbA1c reduction might be different in differing populations.

Funding

None.

Introduction

Type 2 diabetes mellitus is a well established risk factor for cardiovascular disease. Several observational studies have shown a positive correlation between measures of glycaemic control and both cardiovascular outcomes and microvascular disease, independent of risk factors known to cluster with diabetes.1, 2, 3 Consequently, randomised controlled trials have aimed to assess whether more intensive control of glucose reduces long-term clinical events and lengthens lifetime compared with standard treatment. By contrast with the substantial benefits to microvascular outcomes,4, 5 individually these trials have failed to show consistent beneficial effects on cardiovascular events.5, 6, 7, 8

Such inconsistent evidence has resulted in the American Heart Association, the American College of Cardiology, and the American Diabetes Association providing a conservative class IIb recommendation with level of evidence A9 for the benefit of glycaemic control on cardiovascular disease. However, individually these trials might have been underpowered to show clinical benefit—especially if event rates were lower than were expected because of improved control of risk factors; duration of treatment was shorter than was needed to show a clinical benefit;10 or differences in glycaemic control between patient groups were too small to show any benefit. To address such uncertainties, we quantitatively assessed whether intensive glucose-lowering treatment in individuals with type 2 diabetes mellitus resulted in a reduction of cardiovascular events and all-cause mortality. We present data from a meta-analysis of randomised controlled clinical trials, which aimed to assess the effect of differential glycaemic control on cardiovascular outcomes.

Section snippets

Data sources

We searched Medline, Cochrane Central, and EmBase for articles published in English from January, 1970, to January, 2009, with terms related to diabetes and vascular outcomes (eg, “cardiovascular diseases”, “diabetes mellitus”, “glucose”, and “HbA1c”). We restricted the search to randomised controlled trials. This search provided 2439 articles, which were further screened for inclusion from titles, abstracts, or full texts, or a combination of these. We supplemented the electronic search from

Results

Table 1 shows the study design, baseline demographic characteristics of participants, duration of follow-up, and mean HbA1c concentration in the five randomised controlled trials. The criteria for diagnosis of type 2 diabetes and eligibility for the studies are shown on webappendix p 2. 33 040 participants were enrolled from predominantly western populations (table 1). UKPDS4, 7 enrolled individuals within 1 year after diagnosis, whereas the remaining four studies enrolled participants with

Discussion

This meta-analysis of five relevant randomised controlled trials has shown consistently that intensive glucose-lowering treatment has cardiovascular benefit compared with standard treatment for individuals with type 2 diabetes. During about 5 years of treatment, reduction of HbA1c concentration by 0·9% resulted in a significant 17% reduction in events of non-fatal myocardial infarction, a significant 15% reduction in events of coronary heart disease, and a non-significant 7% reduction in events

References (31)

  • S Schor

    The University Group Diabetes Program. A statistician looks at the mortality results

    JAMA

    (1971)
  • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

    Lancet

    (1998)
  • HC Gerstein et al.

    Effects of intensive glucose lowering in type 2 diabetes

    N Engl J Med

    (2008)
  • JS Skyler et al.

    Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association

    Circulation

    (2009)
  • RR Holman et al.

    10-year follow-up of intensive glucose control in type 2 diabetes

    N Engl J Med

    (2008)
  • Cited by (0)

    These authors contributed equally

    View full text